Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

DB10284ApprovedInvestigationalVaccines

Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by Neisseria meningitidis... It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and...

First approval
Canada, 2017 · United States, 2014 · European Union, 2021
Brand names
  • Penbraya
  • Trumenba

Resolves to

Compound
UNII583WCD0IZI
Clinical / RWD
RxNorm1593127

What you can answer from here — as of April 02, 2025

11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
16Marketed productsAcross 5 countries and 4 labellers
Sign in

Which other approved drugs treat the same conditions as Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In